Vendor, Cary, NC
Biolink Life Sciences, Inc.
UEI GUSQRGKRZ4C9, CAGE 1WR74
1 award and -$542,764 obligated between May 14, 2024 and July 16, 2025, 0% under full and open competition, against 100.0 offers on average where reported.
Sells to
Awarding agencies by dollars.
| Office of Assistant Secretary for Preparedness and Response | -$542,764 |
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | -$542,764 |
How it wins
Awards by competition, set-aside and type.
| Competed Under SAP | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50122C00068Definitive Contract, May 14, 2024, Competed Under SAP, 100 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | Biolink - to Investigate and Determine If Treatment with Ramatroban, Administered for 28 Days to Hospitalized, NON-ICU Patients with Covid-1NAICS 541715, PSC AN15 | -$542,764 |
- Places of performance
- North Carolina
- Product and service codes
- AN15 Health R&D Services; Health Care Services; Expenses For R&D Facilities And Major Equipment
- Transactions
- 2 across 1 awards